此页面是自动翻译的，不保证翻译的准确性。请参阅英文版对于源文本。

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

2013年2月4日更新者：National Cancer Institute (NCI)

A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL)

Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

研究概览

地位

完全的

条件

干预/治疗

药品：奈拉滨

详细说明

OBJECTIVES:

I. Determine the complete and partial remission rates, as well as the remission duration, in patients with refractory or relapsed T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma receiving 506U78 on an alternate day schedule (days 1, 3, 5).

II. Determine the safety and toxicity of 506U78 administered on this schedule to this patient population.

OUTLINE:

Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.

研究类型

介入性

注册 (实际的)

阶段

阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

美国
- Alabama
  - Mobile、Alabama、美国、36688
    - MBCCOP - Gulf Coast
- Arizona
  - Phoenix、Arizona、美国、85006-2726
    - CCOP - Greater Phoenix
  - Phoenix、Arizona、美国、85012
    - Veterans Affairs Medical Center - Phoenix (Hayden)
  - Tucson、Arizona、美国、85724
    - Arizona Cancer Center
  - Tucson、Arizona、美国、85723
    - Veterans Affairs Medical Center - Tucson
- Arkansas
  - Little Rock、Arkansas、美国、72205
    - University of Arkansas for Medical Sciences
  - Little Rock、Arkansas、美国、72205
    - Veterans Affairs Medical Center - Little Rock (McClellan)
- California
  - Duarte、California、美国、91010-3000
    - Cancer Center and Beckman Research Institute, City of Hope
  - Long Beach、California、美国、90822
    - Veterans Affairs Medical Center - Long Beach
  - Los Angeles、California、美国、90095-1781
    - Jonsson Comprehensive Cancer Center, UCLA
  - Los Angeles、California、美国、90033-0804
    - USC/Norris Comprehensive Cancer Center and Hospital
  - Los Angeles、California、美国、90073
    - Veterans Affairs Medical Center - West Los Angeles
  - Martinez、California、美国、94553
    - Veterans Affairs Outpatient Clinic - Martinez
  - Oakland、California、美国、94609-3305
    - CCOP - Bay Area Tumor Institute
  - Orange、California、美国、92868
    - Chao Family Comprehensive Cancer Center
  - Sacramento、California、美国、95817
    - University of California Davis Medical Center
  - Santa Rosa、California、美国、95403
    - CCOP - Santa Rosa Memorial Hospital
  - Stanford、California、美国、94305
    - Stanford University
  - Travis Air Force Base、California、美国、94535
    - David Grant Medical Center
- Colorado
  - Denver、Colorado、美国、80220
    - Veterans Affairs Medical Center - Denver
  - Denver、Colorado、美国、80010
    - University of Colorado Cancer Center
- Georgia
  - Atlanta、Georgia、美国、30342-1701
    - CCOP - Atlanta Regional
  - Fort Gordon、Georgia、美国、30905-5650
    - Dwight David Eisenhower Army Medical Center
- Hawaii
  - Honolulu、Hawaii、美国、96813
    - Cancer Research Center of Hawaii
- Illinois
  - Chicago、Illinois、美国、60612-7323
    - MBCCOP - University of Illinois at Chicago
  - Decatur、Illinois、美国、62526
    - CCOP - Central Illinois
  - Hines、Illinois、美国、60141
    - Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
  - Maywood、Illinois、美国、60153
    - Loyola University Medical Center
- Kansas
  - Kansas City、Kansas、美国、66160-7357
    - University of Kansas Medical Center
  - Wichita、Kansas、美国、67214-3882
    - CCOP - Wichita
  - Wichita、Kansas、美国、67218
    - Veterans Affairs Medical Center - Wichita
- Kentucky
  - Lexington、Kentucky、美国、40511-1093
    - Veterans Affairs Medical Center - Lexington
  - Lexington、Kentucky、美国、40536-0084
    - Albert B. Chandler Medical Center, University of Kentucky
- Louisiana
  - New Orleans、Louisiana、美国、70112
    - Tulane University School of Medicine
  - New Orleans、Louisiana、美国、70112
    - MBCCOP - LSU Health Sciences Center
  - Shreveport、Louisiana、美国、71130-3932
    - Louisiana State University Health Sciences Center - Shreveport
  - Shreveport、Louisiana、美国、71130
    - Veterans Affairs Medical Center - Shreveport
- Massachusetts
  - Boston、Massachusetts、美国、02118
    - Boston Medical Center
  - Jamaica Plain、Massachusetts、美国、02130
    - Veterans Affairs Medical Center - Boston (Jamaica Plain)
- Michigan
  - Ann Arbor、Michigan、美国、48109-0752
    - University of Michigan Comprehensive Cancer Center
  - Ann Arbor、Michigan、美国、48105
    - Veterans Affairs Medical Center - Ann Arbor
  - Ann Arbor、Michigan、美国、48106
    - CCOP - Ann Arbor Regional
  - Detroit、Michigan、美国、48202
    - Henry Ford Hospital
  - Detroit、Michigan、美国、48201-1379
    - Barbara Ann Karmanos Cancer Institute
  - Detroit、Michigan、美国、48201-1932
    - Veterans Affairs Medical Center - Detroit
  - Grand Rapids、Michigan、美国、49503
    - CCOP - Grand Rapids Clinical Oncology Program
  - Southfield、Michigan、美国、48075-9975
    - Providence Hospital - Southfield
- Minnesota
  - Duluth、Minnesota、美国、55805
    - CCOP - Duluth
- Mississippi
  - Biloxi、Mississippi、美国、39531-2410
    - Veterans Affairs Medical Center - Biloxi
  - Jackson、Mississippi、美国、39216-4505
    - University of Mississippi Medical Center
  - Jackson、Mississippi、美国、39216
    - Veterans Affairs Medical Center - Jackson
  - Keesler AFB、Mississippi、美国、39534-2576
    - Keesler Medical Center - Keesler AFB
- Missouri
  - Kansas City、Missouri、美国、64128
    - Veterans Affairs Medical Center - Kansas City
  - Kansas City、Missouri、美国、64131
    - CCOP - Kansas City
  - Saint Louis、Missouri、美国、63110-0250
    - St. Louis University Health Sciences Center
  - Saint Louis、Missouri、美国、63141
    - CCOP - St. Louis-Cape Girardeau
  - Springfield、Missouri、美国、65807
    - CCOP - Cancer Research for the Ozarks
- Montana
  - Billings、Montana、美国、59101
    - CCOP - Montana Cancer Consortium
- New Mexico
  - Albuquerque、New Mexico、美国、87108-5138
    - Veterans Affairs Medical Center - Albuquerque
  - Albuquerque、New Mexico、美国、87131
    - MBCCOP - University of New Mexico HSC
- New York
  - New York、New York、美国、10032
    - Herbert Irving Comprehensive Cancer Center
- North Carolina
  - Winston-Salem、North Carolina、美国、27104-4241
    - CCOP - Southeast Cancer Control Consortium
- Ohio
  - Cincinnati、Ohio、美国、45219
    - Barrett Cancer Center, The University Hospital
  - Cincinnati、Ohio、美国、45220-2288
    - Veterans Affairs Medical Center - Cincinnati
  - Cleveland、Ohio、美国、44195
    - Cleveland Clinic Taussig Cancer Center
  - Columbus、Ohio、美国、43206
    - CCOP - Columbus
  - Dayton、Ohio、美国、45428
    - Veterans Affairs Medical Center - Dayton
  - Kettering、Ohio、美国、45429
    - CCOP - Dayton
  - Toledo、Ohio、美国、43623-3456
    - CCOP - Toledo Community Hospital Oncology Program
- Oklahoma
  - Oklahoma City、Oklahoma、美国、73104
    - Veterans Affairs Medical Center - Oklahoma City
  - Oklahoma City、Oklahoma、美国、73190
    - University of Oklahoma Health Sciences Center
- Oregon
  - Portland、Oregon、美国、97207
    - Veterans Affairs Medical Center - Portland
  - Portland、Oregon、美国、97213
    - CCOP - Columbia River Program
  - Portland、Oregon、美国、97201-3098
    - Oregon Cancer Center
- South Carolina
  - Greenville、South Carolina、美国、29615
    - CCOP - Greenville
  - Spartanburg、South Carolina、美国、29303
    - CCOP - Upstate Carolina
- Texas
  - Dallas、Texas、美国、75235-9154
    - Simmons Cancer Center - Dallas
  - Fort Sam Houston、Texas、美国、78234
    - Brooke Army Medical Center
  - Galveston、Texas、美国、77555-0209
    - University of Texas Medical Branch
  - Lubbock、Texas、美国、79423
    - Texas Tech University Health Science Center
  - San Antonio、Texas、美国、78284-7811
    - University of Texas Health Science Center at San Antonio
  - San Antonio、Texas、美国、78284
    - Veterans Affairs Medical Center - San Antonio (Murphy)
  - Temple、Texas、美国、76504
    - Veterans Affairs Medical Center - Temple
  - Temple、Texas、美国、76508
    - CCOP - Scott and White Hospital
- Utah
  - Salt Lake City、Utah、美国、84148
    - Veterans Affairs Medical Center - Salt Lake City
  - Salt Lake City、Utah、美国、84112
    - Huntsman Cancer Institute
- Washington
  - Seattle、Washington、美国、98101
    - CCOP - Virginia Mason Research Center
  - Seattle、Washington、美国、98104
    - Swedish Cancer Institute
  - Seattle、Washington、美国、98108
    - Veterans Affairs Medical Center - Seattle
  - Tacoma、Washington、美国、98431-5000
    - Madigan Army Medical Center
  - Tacoma、Washington、美国、98405-0986
    - CCOP - Northwest

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

16年及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

DISEASE CHARACTERISTICS:

Histologically confirmed diagnosis of T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL)
Leukemia or lymphoma cells should express at least two of the following cell surface antigens: CD1a, CD2, CD3 (surface or cytoplasmic), CD4, CD5, CD7, and CD8
Leukemia cells should be negative for myeloperoxidase or Sudan Black B If the only T cell markers present are CD4 and CD7, the leukemic cells should be demonstrated to lack the myeloid markers CD33 and/or CD13
Refractory to at least one induction treatment regimen or in first or later relapse after achieving a complete remission
No CNS leukemia or lymphoma requiring intrathecal or craniospinal radiotherapy

PATIENT CHARACTERISTICS:

Age: 16 and over
Bilirubin no greater than 2 times upper limit of normal (unless due to leukemia)
Creatinine clearance at least 50 mL/min (unless due to leukemia)
No neurologic toxicity of grade 3 or greater during prior treatment of ALL/LBL
No preexisting neuropathy of grade 2 or greater regardless of causality
No history of seizure disorder
Not pregnant or nursing
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

No concurrent erythropoietin
No other concurrent chemotherapy
No concurrent dexamethasone or other steroidal antiemetics
No concurrent hormone therapy, except for non-disease-related conditions

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

主要用途：治疗
分配：不适用
介入模型：单组作业
屏蔽：无（打开标签）

手臂数量

武器和干预

参与者组/臂	干预/治疗
实验性的：Arm I Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.	药品：奈拉滨

参与者组/臂

干预/治疗

实验性的：Arm I

药品：奈拉滨

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

National Cancer Institute (NCI)

合作者

Southwest Oncology Group

调查人员

学习椅：Steven E. Coutre, MD、Stanford University
学习椅：Daniel DeAngelo, MD, PhD、Dana-Farber Cancer Institute

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. doi: 10.1182/blood-2006-11-056754. Epub 2007 Mar 7.
De Angelo DJ, Yu D, Dodge RK, et al.: A phase II study of 2-amino-9-b-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-Lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. [Abstract] Blood 100 (11 Pt 1): A-743, 2002.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

1998年8月1日

初级完成 (实际的)

2007年3月1日

研究注册日期

首次提交

1999年11月1日

首先提交符合 QC 标准的

2004年2月13日

首次发布 (估计)

2004年2月16日

研究记录更新

最后更新发布 (估计)

2013年2月5日

上次提交的符合 QC 标准的更新

2013年2月4日

最后验证

2007年4月1日

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL)

研究概览

地位

条件

干预/治疗

详细说明

研究类型

注册 (实际的)

阶段

联系人和位置

学习地点

参与标准

资格标准

适合学习的年龄

接受健康志愿者

有资格学习的性别

描述

学习计划

研究是如何设计的？

设计细节

手臂数量

武器和干预

参与者组/臂

干预/治疗

合作者和调查者

赞助

合作者

调查人员

出版物和有用的链接

一般刊物

研究记录日期

研究主要日期

学习开始

初级完成 (实际的)

研究注册日期

首次提交

首先提交符合 QC 标准的

首次发布 (估计)

研究记录更新

最后更新发布 (估计)

上次提交的符合 QC 标准的更新

最后验证

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号